1

2
Tarran Jones
Tsuchiya Masayuki, Sato Koh, Bendig Mary Margaret, Jones Steven Tarran, Saldanha Jose William: Reconstituted human antibody against human interleukin 6 receptor.. Chugai Pharmaceutical, December 14, 1994: EP0628639-A1 (54 worldwide citation)

A reconstituted human antibody against a human interleukin 6 receptor (IL-6R), which is composed of: (A) an L chain composed of (1) the C region of a human L chain and (2) the V region of an L chain comprising the framework region (FR) of a human L chain and the complementarity-determining region (C ...


3
Tarran Jones
Gregory J LaRosa, Christopher Horvath, Walter Newman, S Tarran Jones, Siobhan H O Brien, Theresa O Keefe: Humanized anti-CCR2 antibodies and methods of use therefor. Millennium Pharmaceuticals, Lando & Anastasi, July 24, 2012: US08227211 (3 worldwide citation)

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the intera ...


4
Tarran Jones
LAROSA GREGORY J, HORVATH CHRISTOPHER, NEWMAN WALTER, JONES S TARRAN, O BRIEN SIOBHAN, O KEEFE THERESA: ANTICORPS HUMANISES ANTI-CCR2 ET PROCEDES DUTILISATION DE CES ANTICORPS, HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR. MILLENNIUM PHARMACEUTICALS, MILLENNIUM PHARMACEUTICALS, GOWLING LAFLEUR HENDERSON, May 21, 2013: CA2399080

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor (2) (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the inte ...


5
Tarran Jones
Paul D Ponath, Douglas J Ringler, S Tarran Jones, Walter Newman, José Saldanha, Mary M Bendig: Humanized immunoglobulin reactive with α4β7 integrin. Millennium Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, July 22, 2008: US07402410

The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for α4β7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having binding specificity for α ...


6
Gregory P Winter: Recombinant altered antibodies and methods of making altered antibodies. Medical Research Council, Spencer Frank & Schneider, July 6, 1993: US05225539 (1065 worldwide citation)

An altered antibody is produced by replacing the complementarity determining regions (CDRs) of a variable region of an immunoglobulin (Ig) with the CDRs from an Ig of different specificity, using recombinant DNA techniques. The gene coding sequences for producing the altered antibody may be produced ...


7
Paul J Carter, Leonard G Presta: Humanized antibodies and methods for making them. Genentech, Wendy M Lee, April 25, 2000: US06054297 (468 worldwide citation)

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.


8
William J Dower, Steven E Cwirla: Recombinant library screening methods. Affymax Technologies, Townsend and Townsend Khourie and Crew, June 27, 1995: US05427908 (451 worldwide citation)

Nucleotide sequences encoding proteins of interest are isolated from DNA libraries using bacteriophage to link the protein to the sequence which encodes it. DNA libraries are prepared from cells encoding the protein of interest and inserted into or adjacent to a coat protein of a bacteriophage vecto ...


9
Padlan Eduardo A, Mark George E Iii, Daugherty Bruce L: A method for reducing the immunogenicity of antibody variable domains.. Merck & Co, Nat Inst Health, December 23, 1992: EP0519596-A1 (410 worldwide citation)

A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligand binding properti ...


10
Cabilly Shmuel, Holmes William Evans, Wetzel Ronald Burnell, Heyneker Herbert Louis, Riggs Arthur Dale: Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor.. Genentech, Hope City, November 14, 1984: EP0125023-A1 (379 worldwide citation)

Recombinant DNA techniques are used to produce both immunoglobulins which are analogous to those normally found in vertebrate systems and to take advantage of these gene modification techniques to construct chimeric or other modified forms.